<DOC>
	<DOCNO>NCT02404103</DOCNO>
	<brief_summary>The purpose study see two dos Flunisolide HFA ( FDA approve inhaled medication treat asthma ) affect small airway child asthma .</brief_summary>
	<brief_title>Flunisolide HFA Children With Small Airway Disease</brief_title>
	<detailed_description>This prospective , randomize , parallel , open label study . The primary aim compare average change spirometric value ( Forced expiratory volume 1 ( FEV1 ) Forced Expiratory Flow 25-75 % ( FEF 25-75 % ) Impulse Oscillometry System ( IOS ) value ( Resistance 5 Hz ( R5 ) , Resistance 20 Hz ( R20 ) , Area reactance ( AX ) , Resonant frequency ( Fres ) ) baseline week 6 participant randomize flunisolide hydrofluoroalkane ( HFA ) 1 inhalation BID flunisolide HFA 2 inhalation BID . The change score baseline six week follow initially compare use paired t-tests Chi-squared test trend . Repeated measurement analyze use generalize linear mixed-effects regression modeling ( GLMM ) technique . For continuous outcome ( e.g . FEV1 , FEF 25-75 % , Fres , reactance 5 Hz ( X5 ) , AX , R5-R20 ) . The identity link function normal distribution use . For count data ( e.g. , use Beta-agonists , episode coughing , episodes wheezing , etc . ) log link function Poisson distribution use . If dichotomize outcome ( e.g. , Beta-agonist use , cough occur , etc . ) logit link function Bernoulli distribution use .</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Flunisolide</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<criteria>Diagnosis asthma pediatrician asthma specialist Informed consent parent legal guardian 6 year 18 year age screen visit ability comply medication use , study visit study procedure judge site investigator FEF 2575 % &lt; 65 % predict marker small airway disease Acute wheeze screen visit Baseline visit Acute intercurrent respiratory infection , define increase cough , wheeze , respiratory rate onset 1 week precede screen visit 3 week precede baseline visit Oxygen saturation &lt; 95 % screen visit Baseline visit Clinically significant upper airway obstruction determine Site Investigator ( e.g . severe laryngomalacia , markedly enlarge tonsil , significant snoring , diagnose obstructive sleep apnea . Severe gastroesophageal reflux , define persistent frequent emesis despite antireflux therapy Physical finding would compromise safety subject quality study data determine site investigator Inhaled Corticosteroids ( ICS ) use within 30 day Baseline visit Cystic Fibrosis , Interstitial lung disease ( ILD ) history severe Bronchopulmonary dysplasia ( BPD ) underling significant respiratory disease apart asthma Potential subject pregnant may enroll study</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>